Analytical Data
-
基因名
4-1BBL/TNFSF9
- Application
-
别名
4-1BB ligand receptorCDw137T-cell antigen 4-1BB homologT-cell antigen ILA; CD137
-
种属
Human
-
表达系统
HEK293
-
标签
N- hFc-Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P41273
-
表达区间
71-254aa
-
分子量
48.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
4-1BBL (also known as TNFSF9) is a member of the tumor necrosis factor (TNF) superfamily that plays a critical role in immune regulation and T-cell activation. It interacts with its receptor, 4-1BB (CD137), found on activated T-cells, influencing their proliferation, survival, and cytokine production. Due to its function in enhancing immune responses, 4-1BBL has garnered significant interest in cancer immunotherapy. Researchers are exploring its potential as a therapeutic agent, aiming to boost anti-tumor immunity in various malignancies. Moreover, studies on 4-1BBL and its signaling pathways may reveal insights into T-cell exhaustion and the immune-checkpoint landscape, fostering the development of combination therapies that synergize with existing immune checkpoint inhibitors. The recombinant protein form of 4-1BBL provides a valuable tool for these investigations, allowing scientists to dissect its biological functions, evaluate its effects on different immune cell types, and assess its efficacy in preclinical models. Understanding the mechanisms of 4-1BBL can pave the way for novel therapeutic strategies targeting immune evasion in tumors, making it a focal point in the field of immunotherapy and cancer research.
